
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
New Orleans - A standardized patch test allergen now allows dermatologists to improve diagnosis of allergies related to dust mites, according to Christen M. Mowad, M.D.